- Home
- CSTL vs HUYA Comparison
CSTL vs HUYA Comparison
Compare CSTL & HUYA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CSTL | HUYA |
|---|---|---|
| Founded | 2007 | 2014 |
| Country | United States | China |
| Employees | N/A | N/A |
| Industry | Medical Specialities | Computer Software: Programming Data Processing |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 940.8M | 989.7M |
| IPO Year | 2019 | 2018 |
Fundamental Metrics
Financial Performance| Metric | CSTL | HUYA |
|---|---|---|
| Price | $29.72 | $3.70 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 6 | 1 |
| Target Price | ★ $46.67 | $3.50 |
| AVG Volume (30 Days) | 390.1K | ★ 2.0M |
| Earning Date | 05-18-2026 | 01-01-0001 |
| Dividend Yield | N/A | ★ 65.87% |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $344,229,000.00 | N/A |
| Revenue This Year | $3.15 | $8.78 |
| Revenue Next Year | N/A | $11.22 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 3.66 | N/A |
| 52 Week Low | $14.59 | $2.21 |
| 52 Week High | $44.28 | $4.93 |
Technical Indicators
Market Signals| Indicator | CSTL | HUYA |
|---|---|---|
| Relative Strength Index (RSI) | 33.66 | 43.37 |
| Support Level | $21.77 | $3.55 |
| Resistance Level | $34.97 | $3.99 |
| Average True Range (ATR) | 1.71 | 0.28 |
| MACD | -0.10 | -0.11 |
| Stochastic Oscillator | 31.72 | 5.81 |
Price Performance
Historical ComparisonAbout CSTL Castle Biosciences Inc.
Castle Biosciences Inc is a molecular diagnostics company. The group provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), and uveal melanoma. The product portfolio of the company includes DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test; DecisionDx-SCC, a risk stratification test for cutaneous squamous cell carcinoma; MyPath Melanoma, a diagnostic GEP test for use in patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a test to predict future development of progression of high-grade dysplasia and/or esophageal cancer. It also provides DecisionDx-UM, a risk stratification GEP test. The company also offers its products to the skin cancer and gastroenterology markets.
About HUYA HUYA Inc. American depositary shares each representing one ordinary share
Huya, officially became independent in 2016 and headquartered in Guangzhou, operates live streaming platform focused on games, esports, and interactive entertainment, and also provides game-related services such as distribution and in-game item sales. Its main livestreaming platforms include Huya Live in China and Nimo TV outside of China. As of 2024, Huya was a subsidiary of Tencent, which owned 67% of its equity stake and held 95% of the voting power.